Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
13.84
+0.77 (5.89%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Adlai Nortye Employees
Adlai Nortye had 109 employees as of December 31, 2025. The number of employees decreased by 14 or -11.38% compared to the previous year.
Employees
109
Change (1Y)
-14
Growth (1Y)
-11.38%
Revenue / Employee
$45,872
Profits / Employee
-$325,945
Market Cap
553.60M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 109 | -14 | -11.38% |
| Dec 31, 2024 | 123 | -4 | -3.15% |
| Dec 31, 2023 | 127 | -2 | -1.55% |
| Jun 30, 2023 | 130 | - | - |
| Mar 31, 2023 | 129 | - | - |
| Dec 31, 2022 | 129 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Arvinas | 246 |
| 4D Molecular Therapeutics | 196 |
| ARS Pharmaceuticals | 159 |
| Prime Medicine | 146 |
| Verastem | 102 |
| Silence Therapeutics | 88 |
| Assembly Biosciences | 73 |
ANL News
- 3 days ago - Adlai Nortye submits clinical trial notification to Australia TGA for AN4035 - TheFly
- 3 days ago - Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia - GlobeNewsWire
- 21 days ago - Adlai Nortye doses first patient in AN9025 trial - TheFly
- 21 days ago - Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025 - GlobeNewsWire
- 24 days ago - Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists - GlobeNewsWire
- 6 weeks ago - Cantor starts Adlai Nortye at Overweight, sees 180% upside - TheFly
- 6 weeks ago - Adlai Nortye initiated with an Overweight at Cantor Fitzgerald - TheFly
- 2 months ago - Adlai Nortye Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts